A Phase 1 Multiple Ascending Dose Study Of DS-3032b, An Oral MDM2 Inhibitor, In Subjects With Advanced Solid Tumors Or Lymphomas
Study of DS-3032b in Subjects with Advanced Solid Tumors or Lymphomas
Sponsor: Daiichi Sankyo Pharma Development
Enrolling: Male and Female Patients
IRB Number: AAAN4003
U.S. Govt. ID: NCT01877382
Contact: Gary Schwartz, MD: 646-317-6041 / gks2123@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find the highest dose and the best schedule of the study drug, DS-3032b, that can be given safely in subjects with advanced solid tumors and for subjects that did not respond or no longer respond to standard therapy. DS-3032b works against cancer by blocking the activity of a protein called MDM2. DS-3032b works against cancer by blocking the activity of a protein called MDM2.
This study is closed
Investigator
Gary Schwartz, MD
Do You Qualify?
Do you have an advanced solid tumor that is not responding well to standard treatment? Yes No
Are you able to take oral medication? Yes No
Are you free of any active infection that would interfere with therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Gary Schwartz, MD
gks2123@cumc.columbia.edu
646-317-6041
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE